BCAL Findings Presented at 2023 ASCO Annual Meeting
Highlights Presentation at American Society of Clinical Oncology (ASCO) demonstrates potential to detect breast cancer using plasma lipidomic biomarker signature Results reduce the complexity and advance commercial viability of BCAL test BCAL laboratory now operational to advance clinical research, analytical and clinical validation studies Pathway for laboratory developed test (LDT) to be available to patients and medical community SYDNEY, June 6, 2023 /PRNewswire/ — BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) today announced … Read more